Don't Finalize LDT Guidance, House Appropriators Tell FDA
This article was originally published in The Gray Sheet
Executive Summary
FDA should "suspend further efforts to finalize the laboratory-developed test guidance" and instead work with Congress on a new regulatory pathway for LDTs, House appropriators told the agency in an FY 2017 spending bill, which also adds $10 million to fight the Zika virus.
You may also be interested in...
FDA Puts Lab-Developed Test Oversight Plans On Hold
After years of wrangling over lab-developed test regulations with laboratory lobbyists, FDA has put its plans to finalize a guidance that lays out its oversight framework for LDTs on hold as a new Congress and a new deregulation-focused president-elect is set to take the helm.
House-Senate Conferees Fight Over Zika Funds As FDA Approves More Assays
Emergency funding to battle the summer's mosquito-borne Zika threat is trapped in a military/VA spending bill. Conferees must find a compromise between the House's $622m bid and the Senate's $1.1b offer in the thin stretch of time when both chambers will be session before they adjourn on July 15. In the interim, FDA has authorized more Zika tests.
In Case You Missed It: Top 10 Gray Sheet Stories In April
A podcast interview and a feature story delving into the recent international ISO 13485 quality systems standard revision were the most popular items at TheGraySheet.com last month. Our continuing coverage of off-label communication questions in the courts and the laboratory-developed test debate attracted attention, along with a piece on biocompatibility testing tips from FDA officials. Also: popular Gray Sheet podcasts from April.